Last updated: July 28, 2026
Theophylline 0.2% and Dextrose 5% in Plastic Container: Clinical Trials Update, Market Analysis, and Launch/Exclusivity Outlook
What is theophylline 0.2% in dextrose 5% (D5W) and where is it used?
Theophylline 0.2% in dextrose 5% in a plastic container is an intravenous (IV) admixture intended for administration of the methylxanthine bronchodilator when oral therapy is not feasible. The product strength described corresponds to a 0.2% theophylline concentration in D5W packaged in plastic containers.
Commercial framing depends on the specific branded product name, NDA/ANDA listing, and manufacturer, which determine whether it is positioned as:
- a hospital IV replacement therapy (step-up from oral dosing),
- a short-term bridging therapy (e.g., inability to take tablets),
- or a niche supply item for specific dosing protocols.
Clinical role (high level): Theophylline is used for obstructive airway diseases (commonly asthma and COPD) and has a narrow therapeutic index, making serum monitoring and dosing precision central to clinical practice. IV dosing is typically used when rapid control is needed or when the patient cannot take oral formulations.
What do current clinical trials show for IV theophylline in D5W?
No single, clearly identifiable modern clinical trial program can be stated for the exact product configuration “theophylline 0.2% + dextrose 5% in plastic container” without tying to a specific sponsor, trial registry entry, and investigational product label.
Theophylline trials in recent years typically evaluate:
- alternative dosing strategies,
- adjunct regimens,
- biomarkers or pharmacokinetic drivers,
- and therapeutic drug monitoring protocols,
rather than testing the exact same compounded IV mixture.
Because the request is for a “clinical trials update” tied to the specific marketed formulation, the absence of a uniquely identifiable, public modern trial dataset for this exact mixture prevents an accurate update.
Is there an FDA-approved NDA for theophylline 0.2% in D5W, and what is its regulatory status?
A complete and accurate regulatory-status answer requires:
- the exact brand name or NDC,
- the application type (NDA vs ANDA),
- and the FDA labeling that matches “0.2% theophylline in 5% dextrose, plastic container.”
Without that identifier, the FDA status cannot be stated precisely (approval date, listed indication scope, and whether it is an FDA-approved drug product versus a compounded/marketed specialty supply).
What is the Orange Book status for theophylline 0.2% in D5W plastic containers?
Patent and exclusivity conclusions require the product’s FDA application number so the Orange Book can be linked to:
- listed patents,
- expiration dates,
- pediatric exclusivity,
- and any Orange Book “first applicant” designations.
Without the application identifier, an Orange Book status table would be incomplete and could be inaccurate.
What patents protect IV theophylline formulations in dextrose solutions?
For a formulation like theophylline in D5W, patent coverage often fragments into:
- manufacturing/process improvements,
- stability/compatibility claims in specific container types,
- and any method-of-use or dosing claims tied to monitoring.
A precise “what patents protect” answer depends on the specific application and listed patents. Without that linkage, any patent list risks being wrong.
When does exclusivity expire for theophylline 0.2% in D5W plastic containers?
Exclusivity timelines (useful life, patent term end, regulatory exclusivity) are tied to:
- NDA/ANDA date,
- patent expiration schedules,
- and exclusivity grants listed in FDA systems.
Those cannot be mapped to the exact product strength and packaging description without the application/NDC/brand anchor.
What is the current market size and what drives demand for this specific IV theophylline product?
A defensible market projection needs:
- current sales by NDC or by product name,
- channel mix (hospital/infusion centers vs distributors),
- and supply conditions (whether the product is under shortage or constrained by manufacturing).
For this exact mixture, no verifiable, uniquely attributable market dataset can be produced from the provided prompt alone.
That said, demand drivers in this category typically include:
- hospital formularies for IV bronchodilator bridging,
- ICU and emergency department use patterns,
- therapeutic drug monitoring practices affecting IV theophylline utilization,
- and supply reliability (availability of finished IV theophylline versus alternatives).
How does this IV product compete against other theophylline delivery forms (tablets, elixirs, other IVs)?
Competition is mainly substitution-driven:
- Oral theophylline (immediate or extended release) competes when patients can take oral medication.
- Other IV methylxanthine strategies or bronchodilator protocols compete if clinicians prefer alternative infusion regimens or if theophylline utilization declines due to monitoring burden.
The extent of substitution depends on local guideline adoption, therapeutic drug monitoring infrastructure, and whether alternative IV preparations are easier to obtain.
What generic entry risks exist for theophylline 0.2% in D5W plastic containers?
Generic entry risk depends on:
- patent status,
- FDA approval route for generics (ANDA),
- and whether stability and container compatibility constraints create manufacturing barriers.
Without an Orange Book-linked patent and exclusivity record for the exact product, risk cannot be quantified.
What Paragraph IV challenges or ANDA litigation affects this product?
ANDA litigation tracking also requires:
- the exact branded product and application,
- parties named in the filings,
- and settlement details.
No accurate litigation status can be provided without the application anchor.
Market Projection Framework (What can be stated without brand/NDC mapping)
Theophylline IV solutions represent a specialty, hospital-facing supply segment with demand concentrated in:
- acute care settings,
- formulary inclusion,
- and periods of oral therapy bridging.
A projection for this exact mixture normally models:
- baseline hospital admissions for obstructive airway disease,
- IV conversion rate (percent of patients requiring IV bridging),
- drug cost per treatment and treatment duration assumptions,
- procurement and tender cycles,
- price erosion from generic supply, if patent/exclusivity allow entry.
However, without access to product-specific revenue inputs or regulatory/patent timelines, a quantified projection cannot be produced without risking inaccuracies.
Clinical Development Landscape (Non-specific theophylline trials vs exact formulation trials)
Public theophylline research commonly spans:
- pharmacokinetics and therapeutic drug monitoring,
- dose optimization to reduce toxicity while maintaining bronchodilation,
- and comparative effectiveness in obstructive airway disease management.
This request is for an update tied to “theophylline 0.2% and dextrose 5% in plastic container.” A credible update would require trials that use the same formulation and administration context. No such uniquely mapped trial set can be asserted from the prompt.
Key Takeaways
- Theophylline 0.2% in dextrose 5% in plastic container is an IV formulation used for theophylline delivery when oral administration is not appropriate.
- A product-specific clinical trials update, FDA regulatory status, Orange Book listing, exclusivity schedule, patent estate, and litigation posture cannot be accurately produced from the prompt without a unique product identifier (brand/NDC/application).
- Market sizing and projections for this exact mixture require current sales attribution and regulatory/patent timing to model generic erosion and supply dynamics.
FAQs
- Is IV theophylline still used in asthma and COPD, and how does therapeutic drug monitoring affect utilization?
- How does theophylline’s narrow therapeutic index influence hospital formulary decisions for IV dosing?
- What are the main stability and compatibility considerations for theophylline in dextrose solutions and plastic containers?
- What drives pricing and supply reliability in hospital IV bronchodilator products versus oral theophylline?
- How do patent term and regulatory exclusivity typically affect generic entry timing for IV formulation products?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. U.S. National Library of Medicine.
